NEW YORK, Oct. 13, 2021 /CNW/ — Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the “Company”), a leading biotech company developing psychedelic-inspired therapies, has joined the Clinical Trials Transformation Initiative (CTTI) to contribute in developing and driving adoption of practices that increase the quality and efficiency of clinical trials. MindMed joins CTTI as one…


Previous articleThe Therapeutic Effects of Psychedelics: 2A or Not 2A?-Part 2
Next articlePTSF81 – Somatics, Reframing Trauma, and the 7 Lens Approach, with Liam Farquhar